Biocartis is repositioning its Idylla system for automated sample-to-answer testing in oncology companion diagnostics. The FDA recently granted premarket approval for the Idylla CDx MSI Test, which detects microsatellite instability to guide immunotherapy treatment with Bristol Myers Squibb’s Opdivo and Yervoy. This rapid test features around 2.5-hour turnaround, aiding personalized cancer treatment decisions. CEO Roger Moody emphasizes the company’s strategic focus on oncology and plans for profitability within a year.